JP2012520325A - プレバイオティックオリゴ糖 - Google Patents

プレバイオティックオリゴ糖 Download PDF

Info

Publication number
JP2012520325A
JP2012520325A JP2011554245A JP2011554245A JP2012520325A JP 2012520325 A JP2012520325 A JP 2012520325A JP 2011554245 A JP2011554245 A JP 2011554245A JP 2011554245 A JP2011554245 A JP 2011554245A JP 2012520325 A JP2012520325 A JP 2012520325A
Authority
JP
Japan
Prior art keywords
composition
galactooligosaccharide
weight
less
bifidobacterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011554245A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012520325A5 (https=
Inventor
マリアナ バルボサ
ジェイ． ブルース ジャーマン
カーリト ビー． レブリラ
デビッド エー． ミルズ
サマラ フリーマン
ウィリアム ロバート キング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42728831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2012520325(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of California filed Critical University of California
Publication of JP2012520325A publication Critical patent/JP2012520325A/ja
Publication of JP2012520325A5 publication Critical patent/JP2012520325A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01108—Lactase (3.2.1.108)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pediatric Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011554245A 2009-03-13 2010-03-12 プレバイオティックオリゴ糖 Pending JP2012520325A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16008809P 2009-03-13 2009-03-13
US61/160,088 2009-03-13
PCT/US2010/027206 WO2010105207A1 (en) 2009-03-13 2010-03-12 Prebiotic oligosaccharides

Publications (2)

Publication Number Publication Date
JP2012520325A true JP2012520325A (ja) 2012-09-06
JP2012520325A5 JP2012520325A5 (https=) 2013-04-25

Family

ID=42728831

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011554245A Pending JP2012520325A (ja) 2009-03-13 2010-03-12 プレバイオティックオリゴ糖

Country Status (7)

Country Link
US (3) US8425930B2 (https=)
EP (1) EP2405918B2 (https=)
JP (1) JP2012520325A (https=)
AU (1) AU2010223965A1 (https=)
CA (1) CA2760999A1 (https=)
NZ (1) NZ595174A (https=)
WO (1) WO2010105207A1 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019117212A1 (ja) * 2017-12-12 2019-06-20 森永乳業株式会社 ビフィドバクテリウム属細菌を有効成分とする組成物
JP2019528740A (ja) * 2016-09-19 2019-10-17 プロラクタ バイオサイエンス，インコーポレイテッド 精製ヒトミルクオリゴ糖組成物
JP2022538561A (ja) * 2019-07-01 2022-09-05 ソシエテ・デ・プロデュイ・ネスレ・エス・アー セルピン産生
WO2022191320A1 (ja) * 2021-03-12 2022-09-15 森永乳業株式会社 組成物
JP2025085819A (ja) * 2021-06-03 2025-06-05 森永乳業株式会社 組成物
US12364721B2 (en) 2019-09-24 2025-07-22 Prolacta Bioscience, Inc. Compositions and methods for treatment of inflammatory and immune diseases

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006012536A2 (en) 2004-07-22 2006-02-02 Ritter Andrew J Methods and compositions for treating lactose intolerance
ES2413087T3 (es) 2006-06-13 2013-07-15 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para el diagnóstico y tratamiento del cáncer
WO2008091641A2 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
CN102112490B (zh) 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
EP2400839B1 (en) 2009-02-24 2016-09-07 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
EP3202406A1 (en) 2010-04-28 2017-08-09 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
CA2822219C (en) 2010-12-31 2020-12-29 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
BR112013016606A2 (pt) 2010-12-31 2016-09-27 Abbott Lab processos para redução de incidência de tensão oxidante usando oligossacarídeos de leite humano, vitamina c e agentes antiflamatórios
WO2012158517A1 (en) 2011-05-13 2012-11-22 Glycosyn LLC The use of purified 2'-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics
PH12014500185A1 (en) * 2011-07-22 2019-10-11 Abbott Lab Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
JP5877902B2 (ja) 2011-08-17 2016-03-08 マイクロバイオーム セラピューティクス，エルエルシー バクテロイデス門の胃腸管微生物相対フィルミクテス門の微生物相の比を上昇させるための組成物および製剤の使用
HK1199607A1 (en) 2011-08-29 2015-07-10 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
WO2013082562A1 (en) * 2011-11-30 2013-06-06 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
WO2014138304A1 (en) 2013-03-08 2014-09-12 Axiom Foods, Inc., Rice protein supplements
US9820504B2 (en) 2013-03-08 2017-11-21 Axiom Foods, Inc. Rice protein supplement and methods of use thereof
CA2906984A1 (en) 2013-03-15 2014-09-18 Cargill, Incorporated Carbohydrate compositions
GB201305708D0 (en) 2013-03-28 2013-05-15 Clasado Inc Novel use
AU2015226138B2 (en) * 2014-03-06 2018-11-22 Arla Foods Amba Lactose-reduced milk products containing galacto-oligosaccharides and monosaccharides and a method of production
MA40071A (fr) 2014-07-01 2016-01-07 Probi Usa Inc Comprimés probiotiques bi-couche à double libération
CN107001528A (zh) 2014-07-09 2017-08-01 米德瑞（美国）有限公司 低聚糖组合物及其制备方法
US10835544B2 (en) 2014-12-08 2020-11-17 Glycom A/S Synthetic composition for regulating satiety
EP3229812A4 (en) 2014-12-08 2018-10-03 Glycom A/S Synthetic composition for treating metabolic disorders
US10881674B2 (en) 2014-12-08 2021-01-05 Glycom A/S Synthetic composition for treating metabolic disorders
US10987368B2 (en) 2014-12-08 2021-04-27 Glycom A/S Synthetic composition for preventing or treating CVD
WO2016094836A1 (en) 2014-12-12 2016-06-16 The Regents Of The University Of California Reduction of milk glycans and their degradation products in the neonate gut
HK1246600B (en) 2015-01-26 2020-04-09 Cadena Bio, Inc. Oligosaccharide compositions for use animal feed and methods of producing thereof
PT3071235T (pt) 2015-01-26 2018-02-21 Kaleido Biosciences Inc Produtos terapêuticos de glicanos e respetivos métodos relacionados
WO2016172658A2 (en) * 2015-04-23 2016-10-27 Kaleido Biosciences, Inc. Microbiome regulators and related uses thereof
CA2983236A1 (en) 2015-04-23 2016-10-27 Kaleido Biosciences, Inc. Glycan therapeutics and methods of treatment
ES2886951T3 (es) 2015-09-14 2021-12-21 Glycom As Composición para su uso en la modulación de la microbiota
US10337042B2 (en) 2016-01-12 2019-07-02 Vitalus Nutrition Inc. Method for producing galactooligosaccharides from lactose
WO2019119102A1 (en) * 2017-12-22 2019-06-27 Vitalus Nutrition Inc. Method for producing galactooligosaccharides from lactose
EP3402892A1 (en) * 2016-01-12 2018-11-21 Vitalus Nutrition Inc. Method for producing galactooligosaccharides from lactose
WO2017144062A1 (en) * 2016-02-24 2017-08-31 Glycom A/S Synthetic composition for microbiota modulation
EP3426270A4 (en) 2016-03-11 2020-04-01 Evolve Biosystems, Inc. A TRANSITIONAL COMMENSAL MICROORGANISM TO IMPROVE INTESTINAL HEALTH
ES2924137T3 (es) * 2016-05-05 2022-10-04 Glycom As Composición que comprende HMOS para uso en el tratamiento de la hipersensibilidad y/o dolor visceral mediados por mastocitos
EP4548925A3 (en) 2016-07-01 2025-07-09 Infinant Health, Inc Method for facilitating maturation of the mammalian immune system
US20180030403A1 (en) 2016-07-28 2018-02-01 Bobban Subhadra Devices, systems and methods for the production of humanized gut commensal microbiota
WO2018048305A1 (en) 2016-09-12 2018-03-15 Rijksuniversiteit Groningen Prebiotic branched galacto-oligosaccharides (gos)
CN110114145B (zh) * 2016-10-07 2022-08-09 勃林格殷格翰维特梅迪卡有限公司 用于检测样品的分析系统及方法
EP3634155A4 (en) 2017-05-12 2021-02-17 Axiom Foods Inc. RICE PRODUCTS AND SYSTEMS AND PROCESSES FOR THEIR PRODUCTION
MX2019014315A (es) * 2017-08-04 2020-02-03 Nestle Sa Bacterias probioticas preacondicionadas en un medio que contiene gos y uso de estas.
EP3703705B1 (en) 2017-11-03 2024-05-15 DSM Nutritional Products, LLC Glucose-containing glycan preparations for use in the treatment of hyperammonaemia
KR102032799B1 (ko) * 2017-11-16 2019-10-17 고려대학교 산학협력단 해조류 유래 아가로트리오스의 제조방법 및 프리바이오틱로서의 용도
WO2019123316A1 (en) 2017-12-22 2019-06-27 Glycom A/S Composition comprising hmos for preventing or reducing nociception
US20220010267A1 (en) 2018-05-30 2022-01-13 Evolve Biosystems, Inc. Compostions and method of use for h5 competent bifidobacterium longum subsp. infantis
EP3598901A1 (de) * 2018-07-23 2020-01-29 optiferm GmbH Beta-galactosidase aus l. bulgaricus zur synthese von galactooligosacchariden in molke
CA3108735A1 (en) * 2018-09-06 2020-03-12 Frieslandcampina Nederland B.V. Bifidogenic hypoallergenic gos compositions and methods for providing the same involving beta-galactosidase from a strain of lactobacillus delbrueckii ssp bulgaricus
EP3646739A1 (en) 2018-11-01 2020-05-06 N.V. Nutricia Nutritional composition comprising urea and non-digestible oligosaccharides
US20220325307A1 (en) * 2018-12-03 2022-10-13 Dupont Nutrition Biosciences Aps Use of lactase to provide high gos fiber level and low lactose level
CN109880813B (zh) * 2019-03-20 2022-06-07 安徽大学 一种具有低聚半乳糖合成能力的β-葡萄糖苷酶及其表达菌株和应用
CN111849940B (zh) * 2020-07-28 2022-03-25 量子高科(广东)生物有限公司 一种β-半乳糖苷酶的制备方法及其应用
EP4101301A1 (de) * 2021-06-08 2022-12-14 DMK Deutsches Milchkontor GmbH Verfahren zur herstellung von galactooligosacchariden
US12156859B2 (en) 2021-12-20 2024-12-03 Tainnovation Inc. Methods of and compositions for treating obesity, obesity-related diseases or cancers using a N6-methyllysine/l-lysine mixture
AU2023385606A1 (en) * 2022-11-22 2025-05-15 Fairlife, Llc Process for producing galactooligosaccharides
GB2628547A (en) 2023-03-27 2024-10-02 Univ Newcastle Probiotic and postbiotic compositions, products and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05236981A (ja) * 1992-02-28 1993-09-17 Ajinomoto Co Inc ガラクトオリゴ糖の製造方法
JP2007527199A (ja) * 2003-06-30 2007-09-27 クラサド インコーポレイテッド 新規のガラクトオリゴサッカライド組成物およびその調製法
EP1887017A1 (en) * 2006-08-09 2008-02-13 Friesland Brands B.V. Prebiotic carbohydrate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19701382A1 (de) * 1997-01-16 1998-07-23 Nutricia Nv Kohlenhydratmischung
NZ508867A (en) * 1998-06-17 2003-11-28 New Zealand Dairy Board Bioactive whey protein hydrolysate
FI109602B (fi) * 2001-01-25 2002-09-13 Valio Oy Probioottiyhdistelmä
FR2844453B1 (fr) † 2002-09-13 2006-05-19 Agronomique Inst Nat Rech Utilisation de pre-biotiques pour la prevention de l'installation du diabete de type ii
AU2003282494A1 (en) * 2002-10-11 2004-05-04 Wyeth Nutritional formulations containing synbiotic substances
GB0229015D0 (en) * 2002-12-12 2003-01-15 Novartis Nutrition Ag New Compound
GB0308104D0 (en) * 2003-04-08 2003-05-14 Novartis Nutrition Ag Organic compounds
US20060115465A1 (en) * 2004-10-29 2006-06-01 Macfarlane George Treatment of gastrointestinal disorders
US20070141678A1 (en) * 2005-12-19 2007-06-21 The Procter & Gamble Company Processes for purifying oligosaccharides
PT2076271E (pt) * 2006-10-02 2011-12-02 Friesland Brands Bv Inibição de toxinas da cólera por galacto-oligossacáridos (gos)
WO2008153377A1 (en) † 2007-06-15 2008-12-18 N.V. Nutricia Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05236981A (ja) * 1992-02-28 1993-09-17 Ajinomoto Co Inc ガラクトオリゴ糖の製造方法
JP2007527199A (ja) * 2003-06-30 2007-09-27 クラサド インコーポレイテッド 新規のガラクトオリゴサッカライド組成物およびその調製法
EP1887017A1 (en) * 2006-08-09 2008-02-13 Friesland Brands B.V. Prebiotic carbohydrate

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7510978B2 (ja) 2016-09-19 2024-07-04 プロラクタ バイオサイエンス，インコーポレイテッド 精製ヒトミルクオリゴ糖組成物
KR102821643B1 (ko) 2016-09-19 2025-06-18 프롤랙타 바이오사이언스, 인코포레이티드 정제된 인간 모유 올리고당 조성물
JP7143286B2 (ja) 2016-09-19 2022-09-28 プロラクタ バイオサイエンス，インコーポレイテッド 精製ヒトミルクオリゴ糖組成物
KR20230130667A (ko) * 2016-09-19 2023-09-12 프롤랙타 바이오사이언스, 인코포레이티드 정제된 인간 모유 올리고당 조성물
JP2019528740A (ja) * 2016-09-19 2019-10-17 プロラクタ バイオサイエンス，インコーポレイテッド 精製ヒトミルクオリゴ糖組成物
JP2023002512A (ja) * 2016-09-19 2023-01-10 プロラクタ バイオサイエンス，インコーポレイテッド 精製ヒトミルクオリゴ糖組成物
JPWO2019117212A1 (ja) * 2017-12-12 2020-12-03 森永乳業株式会社 ビフィドバクテリウム属細菌を有効成分とする組成物
WO2019117212A1 (ja) * 2017-12-12 2019-06-20 森永乳業株式会社 ビフィドバクテリウム属細菌を有効成分とする組成物
JP2022538561A (ja) * 2019-07-01 2022-09-05 ソシエテ・デ・プロデュイ・ネスレ・エス・アー セルピン産生
JP7719729B2 (ja) 2019-07-01 2025-08-06 ソシエテ・デ・プロデュイ・ネスレ・エス・アー セルピン産生
US12364721B2 (en) 2019-09-24 2025-07-22 Prolacta Bioscience, Inc. Compositions and methods for treatment of inflammatory and immune diseases
WO2022191320A1 (ja) * 2021-03-12 2022-09-15 森永乳業株式会社 組成物
JP2022139601A (ja) * 2021-03-12 2022-09-26 森永乳業株式会社 組成物
JP2025085819A (ja) * 2021-06-03 2025-06-05 森永乳業株式会社 組成物

Also Published As

Publication number Publication date
CA2760999A1 (en) 2010-09-16
EP2405918B1 (en) 2014-10-22
AU2010223965A1 (en) 2011-10-06
WO2010105207A1 (en) 2010-09-16
US20100254949A1 (en) 2010-10-07
US20140037785A1 (en) 2014-02-06
US20170000811A1 (en) 2017-01-05
NZ595174A (en) 2013-04-26
US8425930B2 (en) 2013-04-23
EP2405918B2 (en) 2020-09-02
EP2405918A4 (en) 2013-01-09
EP2405918A1 (en) 2012-01-18

Similar Documents

Publication Publication Date Title
US8425930B2 (en) Prebiotic oligosaccharides
US10918653B2 (en) Bovine milk oligosaccharides
US8197872B2 (en) Human milk oligosaccharides to promote growth of beneficial gut bacteria
NL2007268C2 (en) Nutritional compositions comprising human milk oligosaccharides and uses thereof.
US10165788B2 (en) Methods and compositions for improved digestion of milk oligosaccharides
JP2022020856A (ja) プレバイオティクスとしての、精製された２’－フコシルラクトース、３－フコシルラクトース、およびラクトジフコテトラオースの使用
TW201233334A (en) Human milk oligosaccharides to promote growth of beneficial bacteria
US20250197436A1 (en) Galactooligosaccharide composition
US20250312388A1 (en) Bifidobacterium infantis formulations
WO2018048305A1 (en) Prebiotic branched galacto-oligosaccharides (gos)
Levantovsky et al. Nutritional requirements of bifidobacteria
WO2024201041A2 (en) Probiotic and postbiotic compositions, products and uses thereof
Mera et al. Biotechnological innovations in pro-, pre-, and synbiotics
CN119403457A (zh) 岩藻糖基化hmo的混合物
HK1260295A1 (en) Bovine milk oligosaccharides
Class et al. Patent application title: BOVINE MILK OLIGOSACCHARIDES Inventors: J. Bruce German (Davis, CA, US) J. Bruce German (Davis, CA, US) David Mills (Davis, CA, US) Carlito B. Lebrilla (Davis, CA, US) Carlito B. Lebrilla (Davis, CA, US) Daniela Barile (Davis, CA, US) Riccardo Locascio (Sacramento, CA, US)
Kumar Evaluation of Probiotic Effectiveness of Certain Functional Fibers
HK1242227A1 (en) Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
JP2016154511A (ja) 資化性菌のスクリーニング方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130306

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140723

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150122